Het eten van veel vlees bereid bij hoge temperaturen geeft
hoger risico op nierkanker
Voeding met veel vlees kan leiden tot een verhoogd risico op
niercelcarcinoom (RCC) door de inname van kankerverwekkende stoffen
door bepaalde kooktechnieken, zoals barbecuen en bakken in de pan.
Het MD Anderson Cancer Center van de Universtiteit aan Texas
publiceerde online in het tijdschrift Cancer, de ontdekking door
zijn onderzoekers dat mensen met bepaalde genetische mutaties
gevoeliger zijn voor de schadelijke stoffen ontstaan tijdens het
koken bij hoge temperaturen.
Lycopeen kan nierkanker voorkomen bij oudere vrouwen
Postmenopauzale vrouwen die regelmatig het
natuurlijk antioxidant lycopeen consumeren verlagen gevoelig hun
risico op een vorm van nierkanker. Lycopeen vindt men in
voedingsmiddelen zoals tomaten, watermeloen en papaja.
Blootstelling aan zonlicht bij
uitoefenen beroep en het risico op nierkanker bij mannen
Volgens een nieuw onderzoek (het grootste
totnutoe op dit vlak), hebben mannen die tijdens de uitoefening van hun beroep veelvuldig
aan zonlicht blootgesteld worden een lager risico op nierkanker dan mannen die binnen
werken. Bij vrouwen vond het onderzoek deze relatie niet. Het onderzoek hield geen
rekening met blootstelling aan zonlicht in de vrije tijd en trekt ook zelf niet de
conclusie dat zonlicht nierkanker kan
Study shows radiofrequency ablation
highly effective in treating kidney tumors
Radiofrequency ablation, a relatively new, minimally invasive treatment, was 100 percent
successful in eradicating small malignant kidney tumors in a study of more than 100
patients, report researchers from Wake Forest University Baptist Medical Center. Of 95
tumors that were smaller than 3.7 cm, all were completely eradicated by a single
treatment, along with 14 of the larger tumors. Total success rate for all tumors was 93
Radiofrequency ablation highly
effective in treating kidney tumors
A relatively new, minimally invasive treatment was 93 percent successful in eradicating
malignant kidney tumors, according to a recent study conducted by researchers from Wake
Forest University Baptist Medical Center in Winston-Salem, N.C.
Reactivating a critical gene lost
in kidney cancer reduces tumor growth
Researchers at Mayo Clinic Jacksonville, have found that a key gene is often
"silenced" in clear cell renal cell carcinoma, the most common type of kidney
cancer, and when they restored that gene in human kidney cancer cells in culture and
animal experiments, tumors stopped growing and many disappeared.
UC Davis discovery offers hope for
treating kidney cancer
Kidney cancer is typically without symptoms until it has spread to other organs, when it
is also the most difficult to treat. Newer chemotherapies show great promise for extending
survival during later disease stages, but they can also be highly toxic. In one of the
first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to
block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for
kidney cancer more effective and better tolerated. The outcome is published in the current
issue of Cancer Biology and Therapy. "Cancer cells are notorious in their ability to
rapidly create copies of themselves. While the latest medications slow down that process,
they do not tend to be curative and have many side effects," said Robert Weiss, a UC
Davis professor of nephrology and chief of nephrology at the Sacramento VA Medical Center.
"We wanted to find ways to help make chemotherapeutics as effective as possible at
the lowest doses possible." Newer medications work by destabilizing cancer cells at
the DNA level, which reduces their ability to replicate. Knowing that the p21 gene has an
important role in restoring cancer cell DNA and potentially circumventing the benefits of
those treatments, Weiss sought to identify compounds that could interrupt this pathway.
Stanford researchers find molecule
that kills kidney cancer cells
Kidney cancer patients generally have one option for beating their disease: surgery to
remove the organ. But that could change, thanks to a new molecule found by Stanford
University School of Medicine researchers that kills kidney cancer cells.
Acrylamide May Hike RCC Risk
DIETARY INTAKE of acrylamide, a probable human carcinogen, may be associated with an
increased risk of renal cell cancer, according to a report in the American Journal of
Clinical Nutrition (2008;87:1428-1438).
research into robotic surgery for kidney cancer
Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is
helping bring the advantages of robotic surgery, including reduced pain and quicker
recovery, to kidney cancer patients.
How less can be more when treating
some kidney cancers
A new Mayo Clinic study suggests that removing the entire kidney from younger patients
with small kidney tumors may lead to decreased overall survival compared with an operation
that removes the tumor but leaves the kidney intact.
Genetic breakthrough offers promise
in tackling kidney tumors
Early tests show promising results for a new treatment for tuberous sclerosis, which can
cause tumors in organs throughout the body. The UK study is led by Cardiff University's
Institute of Medical Genetics, which was the first to identify the genes linked to the
Scientists home in on the origins
of childhood kidney cancer
Scientists at The Institute of Cancer Research have made significant progress in
pinpointing two new risk factors associated with the most common childhood kidney cancer,
known as Wilms tumour. The research published in Clinical Cancer Research today found that
specific genetic changes in certain cells may cause childhood kidney cancer. Lead
scientist, Dr Chris Jones at The Institute of Cancer Research says:This discovery is
a significant step forward and our findings will help locate those who are most at risk
and hopefully lead to earlier diagnosis and better monitoring for patients.The work
is the first to study the entire genome (collection of genes that a person has) within
these clusters of cells by analysing DNA copy number changes. Around one
per cent of children are born with clusters of embryonic cells in their kidneys left over
from growing in the womb. One in a hundred of these children may then go on to develop a
Wilms tumour. With the information from a study published today, doctors will be able to
focus on which of these clusters pose the biggest threat of developing into cancer,
Dr Jones said.Around 70 children are diagnosed with Wilms tumour in the UK each year, the
most common childhood renal cancer, affecting approximately one in every 10,000 children.
Wilms Tumour is very treatable and most children can be cured. However, if both kidneys
are affected the cure rate is lower and it is more difficult to preserve kidney function.
UK kidney cancer patients face
toxic, out-dated treatments with little hope of change
The body that advises the UK Department of Health is likely to rule out four kidney cancer
drugs on cost grounds, despite the fact that they represent the biggest breakthrough in
treatment of the disease in the last 25 years. Professor Eisen of Cambridge University
points out that without them there is no effective treatment for 90 percent of patients
with the disease. The only drugs currently available are toxic, barely effective and
outdated, he adds
A new pharmaceutical drug that halts
progress of metastatic kidney cancer
Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts
progress of metastatic kidney cancer. The work was published recently in the prestigious
international medical journal, The New England Journal of Medicine and involved medical
co-researchers from the Oncology Department of the University Hospital of Navarra, in
collaboration with the Clinical Trials Area of the same Department.
To date the usual treatment for kidney cancer of a metastatic nature has been based solely
on immunotherapy. In phase III of the research sunitinib was compared with interferon (a
type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that
sunitinib is more efficient in halting the progress of the disease. 101 medical centres
from all over the world took part in the research.
Given the short period of follow-up in the research, the effect of the treatment on
survival rates could not be corroborated. Although, in general, the treatment is well
tolerated, certain side effects can occur and have to be taken into consideration -
hypothyroidism, high blood pressure and fatigue.
Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made
least progress in recent years. The usual treatment with immunotherapy had not shown
clearly positive results in many patients. Sunitinib is one of the few pharmaceutical
drugs that provide clear improvements in this type of cancer. The mechanism of functioning
of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to
grow, need to develop blood vessels and this pharmaceutical drug impedes their growth,
blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth.
The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer
with metastasis although, at the University Hospital, it has been employed with over 40
patients for the last two years, using clinical trials.
PET Imaging Identifies Aggressive
Kidney Cancers that Require Surgery
A newly published study demonstrates that imaging with Positron Emission Tomography (PET)
using a radiolabeled antibody accurately identifies whether a patient has clear cell renal
carcinoma -- the most common and aggressive type of renal tumor -- and arms the urologist
with crucial information that will help determine whether surgery is needed.
Sutent achieves first line EAU
approval for kidney cancer
Sutent (sunitinib malate) has received a European Association of Urology recommendation,
as first-line therapy in patients with metastatic renal cell carcinoma of good and
intermediate risk, just two months after gaining EU marketing authorization for first line
use in all patients with advanced and/or metastatic renal cell carcinoma.
Cryoablation -- A New Treatment
Option for Some Kidney Tumor Patients
Mayo Clinic researchers report that freezing kidney tumors through percutaneous
cryoablation shows promise for patients who are not good candidates for surgery. Their
early findings showing short-term success in more than 90 percent of selected patients are
published in this month's issue of Radiology.
Glowing Dye Improves Cancer Removal
A new way to provide clear images of cancerous tumors in the kidney during surgery
promises to help physicians preserve as much kidney function as possible while still
removing all the malignant tissue a significant advance as doctors discover that
saving as much healthy kidney tissue as possible is crucial for the future health of